1. Home
  2. CRSP vs GEF Comparison

CRSP vs GEF Comparison

Compare CRSP & GEF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CRSP
  • GEF
  • Stock Information
  • Founded
  • CRSP 2013
  • GEF 1877
  • Country
  • CRSP Switzerland
  • GEF United States
  • Employees
  • CRSP N/A
  • GEF N/A
  • Industry
  • CRSP Biotechnology: Biological Products (No Diagnostic Substances)
  • GEF
  • Sector
  • CRSP Health Care
  • GEF
  • Exchange
  • CRSP Nasdaq
  • GEF Nasdaq
  • Market Cap
  • CRSP 3.4B
  • GEF 3.2B
  • IPO Year
  • CRSP 2016
  • GEF N/A
  • Fundamental
  • Price
  • CRSP $36.99
  • GEF $54.81
  • Analyst Decision
  • CRSP Buy
  • GEF Buy
  • Analyst Count
  • CRSP 19
  • GEF 7
  • Target Price
  • CRSP $74.35
  • GEF $75.67
  • AVG Volume (30 Days)
  • CRSP 1.6M
  • GEF 165.8K
  • Earning Date
  • CRSP 05-07-2025
  • GEF 02-26-2025
  • Dividend Yield
  • CRSP N/A
  • GEF 3.95%
  • EPS Growth
  • CRSP N/A
  • GEF N/A
  • EPS
  • CRSP N/A
  • GEF 4.43
  • Revenue
  • CRSP $37,314,000.00
  • GEF $5,508,100,000.00
  • Revenue This Year
  • CRSP $49.76
  • GEF N/A
  • Revenue Next Year
  • CRSP $257.28
  • GEF $12.04
  • P/E Ratio
  • CRSP N/A
  • GEF $12.33
  • Revenue Growth
  • CRSP N/A
  • GEF 6.88
  • 52 Week Low
  • CRSP $36.52
  • GEF $53.43
  • 52 Week High
  • CRSP $68.39
  • GEF $73.16
  • Technical
  • Relative Strength Index (RSI)
  • CRSP 34.31
  • GEF 40.74
  • Support Level
  • CRSP $40.41
  • GEF $54.20
  • Resistance Level
  • CRSP $42.72
  • GEF $56.18
  • Average True Range (ATR)
  • CRSP 1.73
  • GEF 1.23
  • MACD
  • CRSP -0.55
  • GEF 0.14
  • Stochastic Oscillator
  • CRSP 0.80
  • GEF 40.43

About CRSP CRISPR Therapeutics AG

Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.

About GEF Greif Inc.

Greif Inc is a producer of industrial packaging products and services with manufacturing facilities located in many countries. It offers a comprehensive line of rigid industrial packaging products, such as steel, fiber, and plastic drums, rigid intermediate bulk containers, closure systems for industrial packaging products, transit protection products, water bottles and remanufactured and reconditioned industrial containers, and services, such as container life cycle management, blending, filling, logistics, warehousing, and other packaging services. The company operates in three reportable business segments including Global Industrial Packaging, Paper Packaging and Services, and Land Management. It operates in USA, Europe, Middle East, Africa and Asia and Other Americas.

Share on Social Networks: